

# Kendall L Mores

## List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4600195/publications.pdf>

Version: 2024-02-01

9  
papers

229  
citations

1478505

6  
h-index

1474206

9  
g-index

13  
all docs

13  
docs citations

13  
times ranked

323  
citing authors

#	ARTICLE	IF	CITATIONS
1	A Review of the Therapeutic Potential of Recently Developed G Protein-Biased Kappa Agonists. <i>Frontiers in Pharmacology</i> , 2019, 10, 407.	3.5	76
2	G protein-biased kratom alkaloids and synthetic carfentanilamide opioids as potential treatments for alcohol use disorder. <i>British Journal of Pharmacology</i> , 2020, 177, 1497-1513.	5.4	53
3	Rubiscoins are naturally occurring G protein-biased delta opioid receptor peptides. <i>European Neuropsychopharmacology</i> , 2019, 29, 450-456.	0.7	27
4	Arrestin recruitment and signaling by G protein-coupled receptor heteromers. <i>Neuropharmacology</i> , 2019, 152, 15-21.	4.1	26
5	Critical Role for Gi/o-Protein Activity in the Dorsal Striatum in the Reduction of Voluntary Alcohol Intake in C57Bl/6 Mice. <i>Frontiers in Psychiatry</i> , 2018, 9, 112.	2.6	25
6	The Meta-Position of Phe4 in Leu-Enkephalin Regulates Potency, Selectivity, Functional Activity, and Signaling Bias at the Delta and Mu Opioid Receptors. <i>Molecules</i> , 2019, 24, 4542.	3.8	10
7	Modulating $\beta^2$ -arrestin 2 recruitment at the $\beta^1$ - and $\beta^4$ -opioid receptors using peptidomimetic ligands. <i>RSC Medicinal Chemistry</i> , 2021, 12, 1958-1967.	3.9	6
8	Identification of a Novel Delta Opioid Receptor Agonist Chemotype with Potential Negative Allosteric Modulator Capabilities. <i>Molecules</i> , 2021, 26, 7236.	3.8	5
9	Therapeutic Potential of G protein-Biased Kratom-Derived and Synthetic Carfentanilamide Opioids for Alcohol Use Disorder. <i>FASEB Journal</i> , 2019, 33, 498.3.	0.5	1